Lv52
890 积分 2026-01-01 加入
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
The evolving role of radiotherapy in advanced non-small cell lung cancer: beyond symptom control
1个月前
已完结
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
1个月前
已完结
Ⅳ期原发性肺癌中国治疗指南（2026版）
2个月前
已关闭
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
3个月前
已完结
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
3个月前
已完结
皖公网安备34019202002308
